Resource
Aion Therapeutic Secures Licensing Agreement for Molecular Iodine Technology
August 2, 2024: Toppen Health has entered into a license agreement with I2Pure for the worldwide rights to its patented molecular iodine for use in water disinfection applications, enhancing Toppen’s advanced water filtration systems.
Aion Therapeutic Responds to First-Ever U.S. Drinking Water Standard Making PFAS Removal a Top Priority
Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") and its water filtration subsidiary, Toppen Health, Inc. ("Toppen" or "Toppen Health"), are excited to share that...
Patent Applications by Toppen Health Transforming Liquid Filtration Effectiveness
Aion Therapeutic Inc. (CSE: AION) (“Aion Therapeutic” or the “Company”), through its water filtration subsidiary, Toppen Health...
Aion Therapeutic Completes Non-Brokered Private Placement Offering of Units
Aion Therapeutic Inc. (CSE: AION) (“Aion Therapeutic” or the “Company”) is pleased to announce that it has completed a non-brokered private placement...
Aion Therapeutic Announces Proposed Non-Brokered Private Placement Offering of Units
Aion Therapeutic Inc. (CSE: AION) (“Aion Therapeutic” or the “Company”) is pleased to announce that it plans to complete a non-brokered private...
Biden-Harris Administration Announces $3 Billion to Deliver Clean Drinking Water to Communities Across the Country
Funding from President Biden’s Investing in America Agenda Will Accelerate Progress Toward the President’s Commitment to Replace Every Lead Pipe...
